Remibrutinib improves quality of life in CSU patients

M. Maurer, A.M. Giménez-Arnau, V. Jain, J. Tillinghast, A. Tolcachier, S. Nigen, K. Hayama,
K. Lheritier, P. Walsh, S. Haemmerle

Poster

Remibrutinib for chronic spontaneous urticaria: Time to complete urticaria control

P. Staubach, M. Maurer, P. Yamauchi, H. Kanavy, A.M. Giménez-Arnau, J. Reed, K. Lheritier,
P. Walsh, I. Nikolaev, S. Haemmerle, M. Lebwohl

Oral Presentation

More patients achieve absence of angioedema with remibrutinib than placebo

M. Maurer, J. Reed, P. Staubach, K. Lheritier, P. Walsh, I. Nikolaev, S. Haemmerle, A. Giménez-Arnau

Poster

Remibrutinib reduces the use of rescue medication in CSU patients

P. Staubach, M. Maurer, J. Reed, K. Lheritier, P. Walsh, I. Nikolaev, S. Haemmerle, A.M. Giménez-Arnau

Poster

Long-term safety and tolerability of remibrutinib in CSU patients

A.M. Giménez-Arnau, M. Maurer, M. Metz, V. Jain, P. Walsh, K. Lheritier, S. Hugot, H. Zouater,
S. Haemmerle, A. Zharkov

Oral Presentation

No increase of infections and infestations with remibrutinib in CSU

M. Metz, A.M. Giménez-Arnau, M. Maurer, A. Tolcachier, S. Haemmerle, K. Lheritier, A. Zharkov

Poster

Remibrutinib versus placebo in CSU patients: REMIX-1 and REMIX-2 trials

M. Hide, M. Maurer, A.M. Giménez-Arnau, S. Saini, M. Lebwohl, G. Sussman, E.D. Martzloff,
K. Lheritier, A. Zharkov, S. Haemmerle

Poster

Remibrutinib improves CSU in patients with low or high IgE

M. Hide, K. Hayama, A. Ramsey, M. Maurer, K. Lheritier, A. Zharkov, S. Haemmerle, I. Nikolaev

Oral Presentation

Remibrutinib improves CSU irrespective of baseline
CU-Index status

M. Maurer, W. Carr, K. Sitz, V. Jain, A.M. Giménez-Arnau, K. Lheritier, I. Nikolaev, S. Haemmerle

Poster

Remibrutinib improves sleep and activity in patients with CSU

A.M. Giménez-Arnau, L. Clore, V. Jain, K. Lheritier, P. Walsh, S. Haemmerle, M. Maurer

Poster

Ligelizumab in chronic spontaneous urticaria: Phase-3 PEARL study results

A.M. Giménez-Arnau, M. Maurer, G. Sussman, S. Saini, M. Hide, L.F. Ensina, V. Varanasi, A. Barve, E. Scosyrev, A. Burciu, E. Hua, M. Patekar, T. Severin

Poster

Angioedema control in CSU correlates with improved health-related QoL

M. Metz, A.M. Giménez-Arnau, M. Maurer, M. Hide, K. Sitz, C.E. Ortmann, M.M. Balp, T. Severin

Poster

Contextual factors analysis guiding an implementation science study in CSU

P.A. Laires, M. Bartezaghi, O. Bonavita, E. Peruzzi, G. Dasari, N. Janssens, V. Herrera, E. Gibbons, J.N. Hill, C. Smith, I. Nikolaev, S. De Geest

Poster

Low QoL scores on UCT associated with poor antihistamine response

A. Rajan, P.A. Laires, N. Janssens, S. Rizvi, S. Smeets, A.M. Giménez-Arnau, K. Weller

Poster

Low UCT scores predicted higher probability of poor antihistamine response

P.A. Laires, A. Rajan, N. Janssens, S. Rizvi, S. Smeets, K. Weller, A.M. Giménez-Arnau

Poster

Low UCT scores predict poor antihistamine response in CSU

A. Rajan, P.A. Laires, N. Janssens, S. Rizvi, S. Smeets, K. Weller

Poster

Urticaria voices: Patients’ and physicians’ perceptions of chronic urticaria

P.A. Laires, M.M. Balp, K. Weller, T.A. Winders, J.A. Bernstein, J.E.M. O’Donoghue, J. Kleebach,
L. Christen, S. Smeets

Poster

CSU has a similar impact on QoL as plaque psoriasis

I. Nikolaev, N. Barbier, C.E. Ortmann, N. Janssens, N. Chapman-Rothe, N. Hajizadeh, O. Hsine,
A. Rajan, P.A. Laires, H. Edgren

Poster

Impact of CSU on patients’ lives: Social media listening analysis

E. Kocaturk, M. Bizjak, E.S. Baldrich, L. Walter, P.T. Montana, L. Christen, N. Janssens, S. Smeets

Poster

PREDICT-CU: Predicting time to clinical remission in chronic urticaria

I. Pivneva, M.M. Balp, Y. Geissbühler, T. Severin, S. Smeets, J. Signorovitch, T. Cornwall,
A. Danyliv, S. Walsh, W. Soong, A. Marsland

Oral Presentation

Remission and comorbidities in chronic spontaneous and chronic inducible urticaria

I. Pivneva, M.M. Balp, A. Danyliv, K. Chen, T. Cornwall, J. Signorovitch, T. Severin, W. Soong,
A. Marsland

Poster

Burden of angioedema in European patients with chronic spontaneous urticaria

M.M. Balp, K. Krupsky, B.L. Balkaran, S. Gupta, C. Lienhard, J. Loh, J. M. Rodriguez Barrios,
A. Romero, D. Patil, S. Walsh, R.K. Kohli, F. Tétart, T. El-Shanawany, J. Reed

Poster

Comparative economic burden of chronic spontaneous urticaria, psoriasis, atopic dermatitis

S. Gupta S., M.M. Balp, S. Walsh, B.L. Balkaran, C. Lienhard, J. Loh, J. M. Rodriguez Barrios,
K. Krupsky, A. Romero, T. El-Shanawany, F. Tétart, J. Reed

Poster

Comparative humanistic burden of chronic spontaneous urticaria, psoriasis, atopic dermatitis

M.M. Balp, S. Walsh, B.L. Balkaran, S. Gupta, K. Krupsky, C. Lienhard, J. Loh, J. M. Rodriguez Barrios, A. Romero, F. Tétart, T. El-Shanawany, J. Reed

Poster

Ligelizumab achieves freedom from CSU-symptoms regardless of previous H₁-antihistamine dose

A. M. Giménez-Arnau, M. Maurer, W. Soong, K. Sitz, J. A. Bernstein, E. Hua, T. Severin

Poster Poster slides

Ligelizumab further improves disease-activity in CSU patients previously on omalizumab

M. Hide, M. Maurer, K. Sitz, G. Sussman, M. Metz, N. Barbier, E. Hua, T. Severin

Poster Poster slides

Ligelizumab further improves sleep in CSU patients previously on omalizumab

M. Metz, A. Giménez-Arnau, M. Hide, M. Maurer, K. Sitz, G. Sussman, N. Barbier, E. Hua, M-M. Balp, T. Severin

Poster Poster slides

Ligelizumab achieves fast symptom control in CSU: Rolling UAS7 analysis

J. A. Bernstein, M. Hide, M. Maurer, A. Giménez-Arnau, W. Soong, S. Acharya, A. Barve, T. Severin

Poster Poster slides

Complete response with ligelizumab in CSU: A composite score analysis

M. Hide, A. Giménez-Arnau, M. Maurer, J. A. Bernstein, K. Sitz, G. Sussman, P. T. Montana, S. Acharya, T. Severin

Poster Poster slides

Ligelizumab for adolescent CSU patients: A dedicated Phase 2b study

P. Staubach, B. E. Sekerel, M. Alvaro-Lozano, M. Maurer, M. Ben-Shoshan, A. Drollmann, A. Bienczak, M. Porter, T. Liu, A. Burciu, T. Severin

Oral Presentation

Ligelizumab shows good stability of response in CSU: Flare-up analysis

M. Maurer, A. Giménez-Arnau, M. Metz, K. Sitz, S. Acharya, N. Barbier, A. Barve, T. Severin

Poster Poster slides

Complete symptom control is associated with improved health-related-quality-of-life in CSU

M. Maurer, A. Giménez-Arnau, J. A. Bernstein, P. Staubach, N. Barbier, E. Hua, Y. Joubert, M-M. Balp, T. Severin

Poster Poster slides

Ligelizumab in chronic inducible urticaria: Phase-3 study design and rationale

M. Metz, M. Bizjak, T. Hawro, S. Altrichter, M. Maurer, S. S. Saini, G. Sussman, A. Giménez-Arnau, M. Hide, A. Barve, M. Porter, S. Smeets, T. Liu, E. Hua, M. Patekar, T. Severin

Poster Poster slides

QoL of CSU patients refractory to H1- antihistamine: AWARE-LACan study

L. F. C. Ensina, F. Dabove, M. Velásquez-Lopera, L. M. T. Quijano, F. DiTata, P. Tassinari

Poster

Pooled analysis of AWARE, LaCAN and AMAC studies: CSU insights

A. M. Giménez-Arnau, M. Maurer, L. F. Ensina, C-Yu Chu, X. Jaumont, P. Tassinari

Poster

Early and sustained treatment with omalizumab significantly improves quality of life in patients with chronic spontaneous urticaria: Analysis from a worldwide real-world database (AWARE Study)

P. A. Laires, N. Janssens, A. Kandra, N. Barbier, C. E. Ortmann, S. Smeets, M-M. Balp, K. Weller

Poster

Complete control of wheals and itch in CSU significantly correlates with better sleep quality: Analysis from a worldwide real-world database (AWARE Study)

P. A. Laires, N. Janssens, A. Kandra, N. Barbier, C. E. Ortmann, S. Smeets, M-M. Balp, K. Weller

Poster

Complete control of wheals and itch in CSU significantly correlates with better patients’ quality of life: Analysis from a worldwide real-world database (AWARE Study)

P. A. Laires, N. Janssens, A. Kandra, N. Barbier, C. E. Ortmann, S. Smeets, M-M. Balp, K. Weller

Poster

Predicting time to remission and identifying influencing factors from a machine learning real-world study

M-M. Balp, I. Pivneva, Y. Geissbühler, T. Severin, S. Smeets, J. Signorovitch, J. Royer, Y. Liang, T. Cornwall, J. Pan, A. Danyliv, W. Soong, A. Marsland

Oral Presentation

Clinical profiles of patients with CSU - a real-world study in the United States

M-M. Balp, Y. Geissbühler, A. Mcconnon, J. Schäl, J. Gomme, P. A. Laires, S. J. McKenna, W. Soong

Poster

Clinical profiles of patients with chronic inducible urticaria: A real-world study in the USA

Y. Geissbühler, M-M. Balp, A. Mcconnon, J. Schäl, J. Gomme, P. A. Laires, S. J. McKenna, W. Soong

Poster

Prevalence and burden of chronic inducible urticaria in Japan

M. Hide, A. Uda, S. Tanaka, F. Maki, N. Miyakawa, S. J. McKenna, S. Gupta, B. Balkaran, M-M. Balp

Poster

Prevalence and burden of chronic spontaneous urticaria in Japan

M. Hide, A. Uda, S. Tanaka, F. Maki, N. Miyakawa, S. J. McKenna, S. Gupta, B. Balkaran, M-M. Balp

Poster

The bruton’s tyrosine kinase inhibitor remibrutinib (LOU064) in chronic spontaneous urticaria: Top line results of a Phase 2b dose-finding study

M. Maurer, A. Giménez-Arnau, W. Berger, V. Jain, K. Hayama, A. Reich, S. Haemmerle, P. Walsh, K. Lheritier, S. Xia, J. Storim

Oral Presentation

2020

Moderate-to-severe CSU patients achieve high complete response rate with ligelizumab

M. Maurer, J.A. Bernstein, A. Giménez-Arnau, W. Soong, G. Sussman, M. Metz, K. Sitz, M. Hide, E. Hua, A. Barve, T. Severin, R. Janocha

Poster

Ligelizumab retreatment achieves high rate of complete response in CSU

M. Metz, M. Maurer, A. Giménez-Arnau, W. Soong, J.A. Bernstein, G. Sussman, M. Hide, K. Sitz, E. Hua, A. Barve, T. Severin, R. Janocha

Poster

Long-term ligelizumab treatment maintains post-treatment symptom-control in CSU patients

A. Giménez-Arnau, M. Metz, W. Soong, J.A. Bernstein, G. Sussman, K. Sitz, M. Maurer, E. Hua, A. Barve, T. Severin, R. Janocha

Poster

Ligelizumab in CSU: Design and rationale of Phase-3b extension study

T. Severin, M. Maurer, A. Giménez-Arnau, M. Hide, G. Sussman, S.S. Saini, E. Hua, A. Barve, Y. Joubert, I. Indermuehle, R. Janocha

Poster

Ligelizumab is effective in CSU patients incompletely controlled with omalizumab

M. Metz, M. Hide, G.L. Sussman, K. Sitz, M. Maurer, T. Severin, R. Janocha, E. Hua

Oral presentations

Fast and complete symptom control with ligelizumab in CSU

A. Giménez-Arnau, M. Maurer, W. Soong, M. Hide, J.A. Bernstein, E. Hua, A. Barve, T. Severin, R. Janocha

Oral presentations

Sleep-interference and urticaria symptoms correlated in the ligelizumab Phase-2b study

A. Giménez-Arnau, M. Maurer, J.A. Bernstein, T. Severin, R. Janocha, M-M Balp, E. Hua

Poster

Complete CSU control with ligelizumab helps normalize quality of life

M. Maurer, J.A. Bernstein, A. Giménez-Arnau, W. Soong, M. Metz, N. Barbier, A. Barve, T. Severin, M.-M. Balp, R. Janocha

Poster

Quality-of-Life correlates with urticaria symptom control: Ligelizumab Phase-2b study data

M. Maurer, A. Giménez-Arnau, J.A. Bernstein, T. Severin, R. Janocha, M-M. Balp, E. Hua

Poster

Exploratory multivariate analysis to predict ligelizumab treatment outcome in CSU

M. Maurer, A. Giménez -Arnau, G. Sussmann, W. Soong, J.A. Bernstein, E. Hua, T. Liu, A. Barve, R. Janocha, T. Severin

Poster

2019

More patients treated with ligelizumab are angioedema-free compared with omalizumab: Results of a phase 2b clinical trial

A. Giménez-Arnau, G. Sussman, M. Maurer, E. Hua, K. Kobayashi, T. Severin, R. Janocha, M-M. Balp

Poster

Ligelizumab achieves sustained control of chronic spontaneous urticaria symptoms of hives, itch and angioedema: 1-year treatment results

J.A. Bernstein, D. Baker, M. Maurer, A. Giménez-Arnau, G. Sussman, A. Barve, E. Hua, T. Severin, R. Janocha

Poster

Ligelizumab reduces rescue medication use in patients with chronic spontaneous urticaria: Phase 2b study results

K. Sitz, W. Soong, B. Lanier, K. Kobayashi, A. Barve, E. Hua, T. Severin, R. Janocha

Poster

Ligelizumab Re-treatment is Highly Effective in Patients with Chronic Spontaneous Urticaria

M. Metz, D. Baker, C. Chu, I. Danilycheva, E. Hua, K. Kobayashi, T. Severin, R. Janocha

Poster

Ligelizumab retreatment is highly effective in patients with chronic spontaneous urticaria

M. Maurer, A. Giménez-Arnau, G. Sussman, E. Hua, T. Severin, R. Janocha

Poster

Ligelizumab is well tolerated and exhibits a safety profile similar to omalizumab and placebo in patients with chronic spontaneous urticaria

G. Sussman, M. Maurer, A. Giménez-Arnau, E. Hua, T. Severin, R. Janocha

Poster

Results from the phase 2b study demonstrate that ligelizumab achieves sustained control of CSU symptoms during treatment-free follow-up

S. Savic, G. Sussman, J.A. Bernstein, J. Hebert, C. Katelaris, E. Hua, A. Barve, T. Severin, R. Janocha

Poster

Study design and rationale of a phase 2b dose-finding study of ligelizumab (QGE031) in adolescent patients with chronic spontaneous urticaria

B. E. Sekerel, A. Drollmann, M. Porter, N. Kataoka, S. Koehne-Voss, M. Maurer, P. Staubach, M. Ben-Shoshan, T. Severin, R. Janocha

Poster

Dose-finding Phase 2 study to evaluate efficacy and safety of the novel BTK inhibitor LOU064 in patients with CSU inadequately controlled by H1-antihistamines

J. Storim, K. Lheritier, S. Hugot, P. End, B. Bieth, B. Cenni, M. Kaul, A. Gimenez-Arnau, M. Maurer, T. Severin

Poster

2018

High Burden of CSU in a Ligelizumab Phase 2b Study

M. Maurer, A. Giménez -Arnau, G. Sussman, J. Loeffler, A. Barve, E. Hua, M.M. Balp, T. Severin, R. Janocha

Poster

Next generation anti-IgE antibody Ligelizumab in CSU: Phase 2b results

M. Maurer, A. Giménez -Arnau, G. Sussman, J. Loeffler, A. Barve, T. Severin, R. Janocha

Oral Presentation

Ligelizumab versus omalizumab in CSU: Phase 3 design and rationale

T. Severin, M. Maurer, A. Giménez -Arnau, G. Sussman, S. Saini, M. Hide, P. Busse, K. Kobayashi, A. Barve, E. Hua, N. Kataoka, R. Janocha

Poster